Can Peptide Therapy Improve Energy by Targeting Mitochondrial Dysfunction?
Mitochondria are the cell’s energy engines. When they stop working efficiently, people often experience the exact symptoms you’d expect: low stamina, exercise intolerance, poor recovery, muscle weakness, and the familiar "wired but tired" pattern.
For that reason, mitochondrial dysfunction is an appealing target for fatigue and performance therapies. At the same time, it is an easy target for hype.
If you spend enough time in peptide forums or longevity clinics, you’ll hear some version of this story: "Your fatigue is mitochondrial. Use a mitochondria-targeted peptide, raise NAD+, and your energy will come back."
There is a kernel of truth in that idea. But it needs tighter framing.
A more accurate takeaway is this:
In some defined situations, mitochondrial-targeted therapies can improve energy-related outcomes or mitochondrial performance. But the strength of evidence varies a lot depending on the compound, the disease, and whether the endpoint is a human fatigue outcome or just a lab marker.
What we’ll cover:
- Why mitochondrial dysfunction is relevant to energy and fatigue
- Why SS-31 / elamipretide has the strongest peptide case
- Why MOTS-c remains promising but early
- Why NAD+ belongs in the conversation but is not a peptide
- Which claims the current evidence actually supports
This guide is for research and educational purposes only. It is not medical advice, and it should not replace evaluation for thyroid disease, anemia, sleep disorders, depression, medication side effects, or other causes of fatigue.
The Core Question: Can Mitochondrial Therapies Improve Energy?
Sometimes, yes.
However, "energy improvement" can mean very different things in research:
- better ATP production in muscle
- improved exercise tolerance
- less disease-related fatigue
- more walking distance
- better muscle function
- subjective improvement in stamina
Those outcomes are related, but they are not interchangeable. A therapy can improve a mitochondrial biomarker without noticeably changing fatigue. It can improve walking distance in one disease and do nothing in another. It can look impressive in mice and still fail in a human trial.
Evidence Snapshot
| Therapy | What It Is | Human Evidence for Energy/Fatigue | Bottom Line |
| Elamipretide (SS-31) | Mitochondria-targeted tetrapeptide | Best human evidence of the group, but still mixed | Most defensible peptide to discuss for mitochondrial energy support |
| MOTS-c | Mitochondrial-derived peptide | Strong mechanistic and animal data, very limited direct human intervention data | Promising, but still mostly preclinical |
| NAD+ / NR / NMN | NAD-related metabolic therapies, not peptides | Mixed human data; some functional signals, many null results | Reasonable to discuss, but not as a proven "energy fix" |
1. SS-31 / Elamipretide: The Strongest Real-World Case
Among the peptides most often discussed for mitochondrial support, SS-31 has the strongest clinical case.
What It Is
SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide designed to localize to the inner mitochondrial membrane and interact with cardiolipin, a lipid that is crucial for mitochondrial membrane structure and respiratory-chain function.
The basic promise is straightforward:
- stabilize mitochondrial structure
- improve electron transport efficiency
- reduce oxidative stress
- support ATP production
As a result, this is a much more direct mitochondrial strategy than the vague "cellular optimization" language used for many longevity compounds.
Mechanistic Human Signal
One of the cleanest human studies on elamipretide was a randomized trial in older adults with impaired mitochondrial function. After a single dose, elamipretide improved in vivo mitochondrial ATP production capacity in skeletal muscle. That was a meaningful proof-of-mechanism finding.
Important catch: fatigue resistance itself did not significantly improve in that short study.
Translation: More importantly, the drug can move mitochondrial energetics in humans, but that does not guarantee immediate symptom relief.
Disease-Specific Human Trials
Elamipretide has also been tested in primary mitochondrial myopathy (PMM), which is much closer to the kind of disease where mitochondria are not just one hypothesis, but the actual core pathology.
An earlier randomized crossover trial in adults with PMM showed a clinically meaningful but not statistically significant improvement in 6-minute walk distance, along with improvements in participant-reported fatigue and muscle complaints. That study created a real efficacy signal and helped justify the larger phase 3 program.
In the MMPOWER-3 phase 3 trial, the study did not meet its primary endpoints, including 6-minute walk distance and fatigue score.
Why Elamipretide Still Matters
Even with those mixed results, elamipretide remained one of the few mitochondrial-targeted therapeutics with enough disease-specific development to make it through the regulatory process.
On September 19, 2025, the FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome, a rare mitochondrial disease. The approval was based on improved muscle strength rather than a direct fatigue endpoint.
The clearest takeaway on SS-31 is:
- it has real human mitochondrial data
- it has real disease-program data
- it has at least one FDA-approved use in a mitochondrial disease
- it is not a universal proven fatigue treatment
For people looking at mitochondrial therapies through an energy lens, elamipretide is the strongest example of a peptide with real human relevance.
Even so, that does not mean SS-31 reliably fixes fatigue in anyone with low energy. Instead, it means there is meaningful human evidence in defined mitochondrial settings, and that puts it ahead of most compounds marketed for "cellular energy."
2. MOTS-c: Biologically Exciting, Clinically Early
MOTS-c is one of the most interesting molecules in the whole mitochondria space.
What It Is
MOTS-c is a mitochondrial-derived peptide encoded within the mitochondrial genome. It is linked to metabolic stress responses, exercise adaptation, and signaling pathways that influence energy handling.
Mechanistically, the literature often highlights:
- AMPK-related signaling
- metabolic stress adaptation
- insulin sensitivity
- exercise-related responses
- maintenance of metabolic homeostasis
Why People Get Excited About It
The preclinical work is genuinely compelling.
- improved insulin sensitivity
- better metabolic flexibility
- improved physical performance in aging models
- support for muscle adaptation under stress
One high-profile 2021 study reported that MOTS-c treatment improved physical capacity in mice across age groups and that late-life intermittent treatment improved physical capacity and healthspan-related measures in older mice.
In humans, that same study also showed that exercise increases endogenous MOTS-c expression in muscle and circulation. That supports its role as a real exercise- and stress-linked signaling peptide in people.
What We Do Not Have Yet
Published literature does not yet show strong randomized human trials demonstrating that administered MOTS-c improves fatigue, stamina, or energy in patients.
Still, while MOTS-c is very attractive biologically, the evidence for actual therapeutic use in humans is still thin.
Bottom line: MOTS-c is a promising mitochondrial signaling peptide with strong mechanistic and animal rationale, but limited direct human therapeutic evidence so far.
3. NAD+ Therapies: Relevant, Popular, and Easy to Overstate
NAD+ deserves a place in this discussion because it is central to cellular energy metabolism and mitochondrial respiration.
NAD+ is not a peptide.
It is a coenzyme involved in redox reactions, mitochondrial metabolism, and many enzyme systems linked to repair and stress response.
Why It Gets Grouped With Peptides
In practice, clinics often bundle NAD+ therapies with peptides because all of them get marketed under the same umbrella:
- energy
- recovery
- anti-aging
- mitochondrial support
Biologically, though, it should be treated as its own category.
Human Data: Mixed
This area is much more mixed than the marketing implies.
Encouraging human finding: a randomized trial in peripheral artery disease found that nicotinamide riboside (NR) improved 6-minute walk distance, which is at least a functional energy-related outcome.
Important negative findings:
- in a 12-week trial in obese, insulin-resistant men, NR did not improve skeletal muscle mitochondrial respiration, content, or morphology
- another human study in older adults found NR augmented the NAD+ metabolome and reduced some inflammatory signals, but did not improve muscle mitochondrial bioenergetics
The most honest summary is:
- NAD-related therapies can affect NAD biology
- some trials show functional benefit in specific populations
- many do not show the kind of clear mitochondrial-energy improvement people expect
What About IV NAD+?
The direct evidence for IV NAD+ is especially weak compared with how often it is marketed.
A recent 2026 retrospective pilot study compared IV NAD+ with IV nicotinamide riboside in a commercial setting. It was mainly a tolerability study, not a true efficacy trial. NAD+ infusions were associated with more infusion-related symptoms, and the study did not establish meaningful energy efficacy.
IV NAD+ should be framed very cautiously.
Practical interpretation: Taken together, NAD-related therapies are fair to include in a mitochondrial energy article, but they should be positioned as mitochondrial metabolism support strategies, not peptides, and their human evidence remains mixed.
So Can These Therapies Improve Energy "In Some Cases"?
Yes, that statement is defensible. Even then, it needs careful wording.
A careful summary would be:
In some cases, therapies that target mitochondrial biology can improve energy-related outcomes such as ATP production, muscle function, or walking performance. Among the compounds commonly discussed in peptide medicine, elamipretide has the strongest direct human evidence, MOTS-c has a strong preclinical rationale, and NAD-related therapies have mixed but sometimes encouraging human data.
What the evidence does not support:
- "MOTS-c restores mitochondrial function in humans"
- "SS-31 fixes fatigue"
- "NAD+ infusions reliably increase energy"
- "Mitochondrial dysfunction is the main cause of most chronic fatigue"
Those claims outrun the evidence.
How the Current Evidence Ranks Them
Based on the current literature, the ranking looks like this:
| Rank | Compound | Why It Ranks Here | Main Limitation |
| 1 | Elamipretide / SS-31 | Direct mitochondrial targeting, human ATP data, disease-program development, FDA approval in a mitochondrial disease | Not a universal fatigue fix; mixed trial outcomes |
| 2 | NAD+ / NR / NMN | Central to mitochondrial metabolism, actual human trials, some functional improvement signals | Not a peptide; human mitochondrial-function results are inconsistent |
| 3 | MOTS-c | Biologically fascinating, strong animal and mechanistic support, clearly tied to metabolism and exercise adaptation | Human therapeutic evidence is still early |
At first glance, that ordering may surprise readers who expect MOTS-c to rank first. However, when human outcomes are weighted more heavily than theoretical appeal, SS-31 deserves the top spot.
Final Verdict
Yes, mitochondrial-targeted therapies can improve energy-related outcomes in some cases.
Even so, that claim is strongest when it is grounded in the actual evidence:
- SS-31 / elamipretide is the most credible peptide example and has the best human case
- MOTS-c is highly promising but still mostly a preclinical story
- NAD+ therapies belong in the discussion, but they are not peptides and their human results are mixed
The strongest version of this claim is not: "These compounds restore energy."
A better way to put it is this: in defined settings involving mitochondrial dysfunction, some mitochondrial-targeted therapies can improve bioenergetic markers, physical function, or fatigue-related outcomes, but the evidence varies sharply by compound and condition.
That framing is less flashy, but much closer to the truth.
Research Sourcing and Vendor Links
Affiliate Disclosure: We may earn a commission if you purchase through the links below. That does not change our editorial standards or how we evaluate products.
Important: The compounds discussed in this article are not interchangeable with FDA-approved treatments for fatigue, mitochondrial disease, thyroid disease, or any other medical condition. This section is provided for readers researching sourcing quality, not for self-treatment guidance.
Ascension coupon code: SUBQPROTOC
Orbitrex coupon code: subqprotocol
If you choose to evaluate vendors, focus on:
- batch-specific COAs
- identity testing and purity testing
- recent documentation dates
- transparent storage and handling practices
- realistic claims rather than disease-treatment promises
Avoid vendors that:
- claim to "cure" fatigue or mitochondrial dysfunction
- position research compounds as substitutes for approved drugs
- provide no batch testing or unverifiable COAs
- rely on dramatic before-and-after claims instead of documentation
Current Research Categories Mentioned in This Article
SS-31 / Elamipretide-related listings: Ascension Peptides | Orbitrex
MOTS-c listings: Ascension Peptides | Orbitrex
NAD+ / NAD-related listings: Ascension Peptides | Orbitrex
Editorial rule: Any affiliate link added here should point only to vendors that meet your minimum documentation standards. If a vendor makes aggressive medical claims or does not provide credible testing documentation, it should not be linked from this article even if the commission is attractive.
Sources & References
- Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.
- Karaa A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
- Karaa A, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
- FDA Grants Accelerated Approval to First Treatment for Barth Syndrome.
- Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
- Wan W, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
- McDermott MM, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial.
- Dollerup OL, et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men.
- Elhassan YS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.
- Reyna K, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting.